Eashwar Krishnan
Eashwar Krishnan's Tybourne Capital holds 4 U.S.-equity positions worth $31M (SEC 13F, Q3 2025). Top positions: Taysha Gene Therapies, Inc. Common Stock 39.1%, Forte Biosciences, Inc. Common Stock 38.1%, Alumis Inc. Common Stock 18.1%. 13F-replication return is +60% over 3 years (-11 pts vs the S&P 500) — a replicated, non-audited figure.
Holdings
| Stock | % of portfolio | Shares | Value | Latest activity | Avg buy price | Current price | Date |
|---|---|---|---|---|---|---|---|
| TSHA Taysha Gene Therapies, Inc. Common Stock | 39.1% | 3.7M | $12M | ▼ 9.6% (−395K) | $0.00 | $6.53 (+338242%) | 2025-09-30 |
| FBRX Forte Biosciences, Inc. Common Stock | 38.1% | 787K | $12M | — | $5.59 | $18.28 (+227%) | 2025-09-30 |
| ALMS Alumis Inc. Common Stock | 18.1% | 1.4M | $6M | — | $3.00 | $24.60 (+720%) | 2025-09-30 |
| ZNTL Zentalis Pharmaceuticals, Inc. Common Stock | 4.7% | 961K | $1M | ▼ 35% (−517K) | $0.02 | $3.67 (+16843%) | 2025-09-30 |
FAQ ▾
What are Eashwar Krishnan's largest holdings?
As of the latest 13F: Taysha Gene Therapies, Inc. Common Stock 39.1%, Forte Biosciences, Inc. Common Stock 38.1%, Alumis Inc. Common Stock 18.1%, Zentalis Pharmaceuticals, Inc. Common Stock 4.7%.
How big is Tybourne Capital's 13F portfolio?
$31M across 4 disclosed U.S.-equity positions.
What is Eashwar Krishnan's 3-year performance?
+60% (13F-replication, price return), -11 pts vs the S&P 500. Not an audited fund return.
Where does this data come from?
U.S. SEC Form 13F-HR institutional holdings filings.
Sourced from SEC Form 13F-HR filings · Not investment advice ▾
Latest activity = change vs. the prior 13F. Avg buy price = est. entry over the trailing 3 years (gain = vs. latest price). Returns are 13F-replication, not audited fund returns. Sourced from SEC 13F filings.